Sustained Efficacy and Safety at Week 52 and Up to Three Years in Adults with Glycogen Storage Disease Type iA (GSDIa): Results from a Phase 1/2 Clinical Trial of DTX401, an AAV8-mediated, Liver-Directed Gene Therapy
MOLECULAR THERAPY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要